Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC

Maria Ignez Braghiroli, MD
Published: Sunday, Oct 09, 2016



Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.

NRAS-mutant mCRC is an aggressive subset of mCRC, and patients typically experience worse overall survival than patients with RAS wild-type tumors of KRAS-mutant mCRC.

This subgroup of patients with NRAS-mutant mCRC tend to have increased left-sided colon primary tumors, and these patients may also have a distinct molecular pathogenesis.


Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.

NRAS-mutant mCRC is an aggressive subset of mCRC, and patients typically experience worse overall survival than patients with RAS wild-type tumors of KRAS-mutant mCRC.

This subgroup of patients with NRAS-mutant mCRC tend to have increased left-sided colon primary tumors, and these patients may also have a distinct molecular pathogenesis.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x